Feature | Holter Monitoring Systems | November 16, 2015| Judy Lenane, RN, MHA

Continuous Heart Monitoring Key to Identifying Cause of Cryptogenic Stroke

Data from continuous monitoring with new generation wearable monitors may help prevent secondary strokes 

wearable Holter monitors, iRhythm, ziopatch, zio patch

iRhythm Technologies Zio Patch was among the first of a new generation of simplified, wearable Holter monitors designed to increase ease of use and patient compliance to increase detection of arrhythmias that may lead to stroke.

Vital Connect, HealthPatch, wearable holter

Vital Connect announced its HealthPatch MD biosensor has received U.S. Food and Drug Administration (FDA) clearance. The solution is capable of capturing clinical-grade biometric measurements and is the first FDA-cleared medical device that includes a fall detection feature. 

ScottCare, Novi, wearable cardiac monitoring

ScottCare's Novi wearable cardiac monitoring device.

BodyGuardian, Preventice Solutions, Boston Scientific

The BodyGuardian wearable cardiac monitoring system from Preventice Solutions. Boston Scientific has invested heavily in Preventice and has become the exclusive worldwide sales and marketing representative for the company. This has enabled Boston Scientific's entry into the ambulatory, noninvasive EP monitoring space. 

One-third of ischemic strokes are classified as cryptogenic. The classic risk factors for stroke are usually absent, such as cardio-embolism or large artery atherosclerosis. In the United States, about 200,000 strokes without a known cause occur annually, according to the American Stroke Association (ASA). What’s even more striking is that a recent American Heart Association (AHA) survey revealed more than half of U.S. physicians admit being uncertain about the best approaches to finding the underlying causes of cryptogenic strokes. 

The ability to clearly identify the root cause of cryptogenic stroke is critical to determine the appropriate diagnosis and course of treatment, resulting in improved patient outcomes. Currently, most patients with cryptogenic stroke are treated with antiplatelet medications and advised to exercise regularly, stop smoking and maintain a healthy diet to minimize secondary stroke risk. However, these treatments are not effective in preventing a secondary stroke resulting from a cardio-embolism. What is needed is long-term, continuous cardiac monitoring for patients who suffered from a cryptogenic stroke to detect any heart rhythm abnormalities such as atrial fibrillation (Afib). 

The risk of stroke is five times greater in individuals with Afib. In fact, studies suggest that up to 30 percent of patients with cryptogenic stroke may have previously undetected paroxysmal Afib. Difficult to diagnose, Afib can go undetected because it often has no symptoms and may occur infrequently. 

A recent study published in Clinical Cardiology found the use of continuous ambulatory electrocardiographic (ECG) monitoring increased the detection and diagnosis of silent Afib in asymptomatic patients with known risk factors. In a high-risk population that had absolutely no symptoms or clinical indication of arrhythmias, the study found Afib in 5 percent of subjects using extended, patch-based screening. 

Additionally, atrial tachycardia, sometimes a pre-cursor to Afib, was found in 6 percent for a combined total of 11 percent detection rate. This pilot study shows that not only is systematic screening of Afib feasible, but it enables the treatment of patients before they develop complications, such as a stroke. This data suggests that Afib should be managed much like diabetes or hypertension, where patients are screened continuously to pre-empt adverse outcomes later.

Additionally, data presented during the 2015 American College of Cardiology (ACC) scientific sessions identified a high burden of paroxysmal arrhythmia among community dwelling elderly men and women. The study analyzed the frequency and prevalence of Afib premature atrial complexes (PACs) and premature ventricular complexes (PVCs), and supraventricular tachycardia (SVT) and non-sustained ventricular tachycardia (NSVT). Notable findings from the study include: 

• Approximately 6 percent of patients experienced AFib. The majority of the participants with paroxysmal AFib did not report a past diagnosis and were not taking anticoagulants.
• Nearly all participants had at least one PAC (96.6 percent) or one PVC (94.5 percent).
• SVTs occurred in 85.3 percent of patients while NSVTs occurred in 26.9 percent of patients.

Most current heart monitoring options, such as the 50-year-old standard Holter monitor, are limited in their ability to identify arrhythmias because they do not capture enough information and do not record for a long enough period of time. They also are often difficult for patients to use or tolerate because of the battery source and multiple leads that must be applied and removed repeatedly, limiting their ability to provide enough needed information to physicians. Furthermore, studies have shown that the lack of diagnosis or the need for additional testing after the initial use of the Holter monitor resulted in $45 million, or slightly more than $23,000 per patient, in unnecessary Medicare spending. When extrapolated over the entire Medicare fees-for-service population, the total was more than $900 million over the two-year study period in unnecessary spending.

New advancements in technology such as wire-free, long-term, continuous cardiac monitors have significantly improved how Afib is diagnosed and managed. The long-term, continuous monitoring allows physicians to rule in, or even rule out, the diagnosis and characterization of Afib and potentially eliminate the need for further testing, resulting in quicker diagnosis and treatment, and ultimately reducing healthcare costs.  

Studies have also shown continuous cardiac monitors ruled-in or ruled-out arrhythmia in an average of three to four weeks compared to only 36 percent of patients obtaining a definitive diagnosis within two years if their initial diagnostic is a Holter monitor. In addition, in patients with arrhythmia, these continuous cardiac monitors provide immediate diagnosis, eliminating the need for additional diagnostic testing and enabling immediate and appropriate treatment 94 percent of the time. As for healthcare costs, preliminary findings showed that use of long-term, continuous cardiac monitors is expected to reduce two-year costs of diagnosing and managing arrhythmia by an average of $5,500 per patient when compared to the Holter monitor.

Continuous cardiac monitoring can help identify the underlying cause for cryptogenic stroke and help physicians determine the best course of treatment. When faced with choosing between antiplatelet therapy or an anticoagulant, understanding the risk factors and root cause are imperative to reduce stroke recurrence. The outcomes of continuous cardiac monitoring will ultimately improve patient outcomes and reduce healthcare costs. 

Editor’s note: Judy Lenane, RN, MHA, is an executive vice president and chief clinical officer at iRhythm, a digital healthcare solutions company focused on advancing cardiac care. Previously, she led cardiovascular services for large healthcare systems before focusing on developing effective and sustainable cardiovascular interventions. Lenane is also a frequent author and speaker. She can be reached at [email protected] 

Related Content

COMPASS Trial Shows Rivaroxaban With Aspirin Improves Stable Cardiovascular Disease
Feature | Antiplatelet and Anticoagulation Therapies| September 12, 2017
September 12, 2017 — Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin
News | Antiplatelet and Anticoagulation Therapies| August 28, 2017
August 28, 2017 — Bristol-Myers Squibb Company and Pfizer Inc.
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Study Discovers Anticoagulant Drugs Are Being Prescribed Against Safety Advice
News | Antiplatelet and Anticoagulation Therapies| July 25, 2017
July 25, 2017 — A study by researchers at the University of Birmingham has shown that general practitioners (GPs) are
Alere point of care POC testing for INR
News | Point of Care Testing| July 17, 2017 | Dave Fornell
July 17, 2017 — Despite issues with point-of-care INR testing company Alere Inc., Abbott announced this week it is on
long-duration dual anti-platelet therapy (L-DAPT) compared to short-duration dual antiplatelet (S-DAPT) after DES stent implantation
News | Antiplatelet and Anticoagulation Therapies| July 12, 2017
June 12, 2017 — Researchers have evaluated the long-term efficacy and safety of long-duration dual anti-platelet ther
FDA Grants Priority Review of Xarelto sNDA for 10 mg Dose
News | Antiplatelet and Anticoagulation Therapies| June 29, 2017
Janssen Research & Development LLC announced the U.S. Food and Drug Administration (FDA) accepted for Priority...
Overlay Init